menu
    • menu

    Company profile for Vivtex

    NEW Drugs in Dev: 1
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Vivtex is at the forefront of revolutionizing drug development through the implementation of a groundbreaking platform technology known as the Gastrointestinal Tract Organ Robotic Interface System (GI-ORIS™). This innovative system allows for robotic screening utilizing fully intact and functional organs. Developed in the Langer lab at MIT, the GI-ORIS™ technology offers versatile applications, such as oral delivery of bio...
    Vivtex is at the forefront of revolutionizing drug development through the implementation of a groundbreaking platform technology known as the Gastrointestinal Tract Organ Robotic Interface System (GI-ORIS™). This innovative system allows for robotic screening utilizing fully intact and functional organs. Developed in the Langer lab at MIT, the GI-ORIS™ technology offers versatile applications, such as oral delivery of biologics, drug toxicity mitigation, and spatial/temporal drug delivery. Vivtex harnesses the distinctive capabilities of GI-ORIS™ to advance the development of new oral therapeutics.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    VivtexUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    300 Cambridge, MA 02139
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vivtex.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vivtex/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novo, Vivtex in up to US$2.1 bn Obesity Deal
    Novo, Vivtex in up to US$2.1 bn Obesity Deal

    27 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/25/3244528/0/en/novo-nordisk-and-vivtex-partner-to-develop-next-generation-oral-medicines-for-obesity-and-diabetes.html

    GLOBENEWSWIRE
    27 Feb 2026
    Share Share
    Orbis And Vivtex Collaborate To Develop Orally Dosable Next-Gen nCycles
    Orbis And Vivtex Collaborate To Develop Orally Dosable Next-Gen nCycles

    17 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240917637940/en

    BUSINESSWIRE
    17 Sep 2024
    Share Share
    Vivtex And Equillium Partner On GI-Targeted Formulations
    Vivtex And Equillium Partner On GI-Targeted Formulations

    16 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/16/2946672/0/en/Vivtex-Enters-New-Research-Agreement-with-Equillium-to-Develop-GI-targeted-Formulations-for-its-First-in-Class-Oral-Bi-Specific-Peptide-Therapy.html

    GLOBENEWSWIRE
    16 Sep 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search